Topic Listing for Raptor Pharmaceutical Corp

Absence Changes Abstentions Broker Non-votes
Acceptance Access Investigation
Access New Product Candidates Through In-house Discovery Efforts Accomplishments
Accounting Firm Accounting Investment Oxis
Accounting Stock Sales Subsidiary Accounts
Accounts Notification Collection Accrued Expenses
Accuracy Representations Acquisition Inquiry
Acquisition Oxis International Inc Acquisition Proposal
Acquisition Transaction Act
Activities Following Adoption Plan Activities Following Adoption Plan Dissolution
Acute Migraine Headaches Acute Toxicity Studies
Additional Compound Additional Conditions Precedent Obligations Axonyx Merger Sub
Additional Indemnity Additional Information Merger Find
Additional Product Additional Restrictions Conditions Issuance Delivery Shares
Addressing Unmet Needs Migraine Sufferers Adjusted Exchange Ratio Calculation
Adjustment Exercise Price Adjustment Provisions
Adjustments Changes Common Stock Corporate Transactions Administration
Adoption New Accounting Standards Advances Milestones Drug Development Programs
Advantages Axonyx Torreypines Combination Affiliate
Affiliates Aggregate Option Exercises 2004 End Values
Aggregate Option Exercises 2005 End Values Agreed Accepted
Agreement Agreement Plan Merger Reorganization
Agreement Providing Johnson Development Corporation Jjdc Right Obtain Agreement Providing Johnson Development Corporation Right Obtain Rights
Agreement Retain Shares Agreements Contracts Commitments
Agreements Other Documents Alterations Maintenance Repairs Replacements
Alternative Royalty Sublicense Fee Alzheimers Disease
Alzheimers Disease Cias Alzheimers Disease Genetics Program
Alzheimers Disease Genetics Research Program Cooperation Agreement Amended Restated Code Business Conduct Ethics
Amended Restated Employment Agreement Amendment
Amendment Development License Agreement Amendment Employment Agreement
Amendment Lease Amendment No1
Amendment Termination Amendment Termination Suspension Plan
Amendments Amendments Articles Incorporation Bylaws Change
Amendments Charter Bylaws Amendments Registrants Code Ethics Waiver Provision
Amendments Writing Integration Ampa Kainate Receptor Antagonists
Amyloid Beta Collaboration Agreement Anda
Annex Schedule Exceptions Annual Incentive Bonus
Annual Meeting Stockholders 2007 Annual Reports
Anti-dilution Provisions Anti-takeover Provisions Stockholder Rights Plan Certificate Incorporation Bylaws
Anticipated 12-month Milestones Anticipated Closing Date
Antitrust Appendix
Applicable Law Jurisdiction Applicable Time
Application 409a Appraisal Rights
Approval 2008 Employee Stock Purchase Plan Approval Plan Dissolution
Approximately Axonyx Shareholders Assignability
Assignment Assignment Binding Effect
Assignment Form Assignment Subletting
Assumed Options Pursuant Torreypines 2000 Equity Incentive Plan Attachment
Attestation Report Registered Public Accounting Firm Attorneys Fees
Attorneys Fees Costs Expenses Attract Retain Develop World-class Scientists Drug Developers Management
Audit Committee Audit Fees
Audit-related Fees Authority Binding Nature Agreement
Authority Procure Loans Authorization Etc
Authorization Financing Statements Authorized Disclosure
Autobahn Acquisition Inc Award Not Service Contract
Axonyx Axonyx Affiliate
Axonyx Announces License Phenserine Daewoong Pharmaceutical South Korea Axonyx Announces Results Interim Analysis Beta- Amyloid Trial
Axonyx Associate Axonyx Board Recommendation
Axonyx Business Strategy Drug Development Programs Axonyx Certificate
Axonyx Contract Axonyx Designated Directors
Axonyx Disclosure Schedule Axonyx Drug Development Programs
Axonyx Employee Plan Axonyx Inc
Axonyx Inc 500 Seventh Avenue Floor New York Axonyx Inc Adopts Shareholder Rights Plan
Axonyx Inc Code Business Conduct Ethics Axonyx Inc Exact Name Registrant Specified Charter
Axonyx Inc Nasdaq Axyx Axonyx Intends Registration Statement Joint Proxy Regarding Merger
Axonyx Interim Balance Sheet Axonyx Material Adverse Effect
Axonyx Material Contract Axonyx Merger Warrant
Axonyx Merger Warrants Axonyx Name Change
Axonyx Pending Litigation Axonyx Permits
Axonyx Permitted Transaction Axonyx Registered
Axonyx Regulatory Permits Axonyx Rights
Axonyx Rights Agreement Axonyx Sec Documents
Axonyx Securities Litigation Axonyx Stock Plans
Axonyx Stockholder Approval Axonyx Stockholders Meeting
Axonyx Torreypines Host Webcast Conference Call Announced Merger Axonyx Triggering Event
Axonyx Warrants Axonyxs Follow-on Compound Positive Isomer Phenserine Appears Decrease
Axonyxs Lead Compound Alzheimers Disease Phenserine Dual Mechanism B-2
Background Background Amyloid Inhibitory Peptides Aips Prion Pips
Background Plan Dissolution Balance Page Intentionally Left Blank
Base Prospectus Base Rent
Base Salaries Base Salary
Basis Consolidation Basis Presentation
Because Depend Parties Acquisition Development Drug Candidates Not Because They Contain Important Information Proposed Merger Transaction
Beneficial Owner Shares Registered Name Broker Bank Beneficial Owner Shares Registered Name Broker Bank Other
Beneficial Ownership Reporting Compliance Benefit Underserved Patient Populations
Benefits Binding Agreement Benefit
Biostatistical Methods Bisnorcymserine Alzheimers Disease
Bisnorcymserine Bnc Bisnorcymserine Development Program
Board Board Directors
Board Directors Abandon Delay Implementation Plan Dissolution Even Board Directors Recommend Vote Proposal Approve Plan Dissolution
Board Directors Recommending Approval Plan Dissolution Board Directors Recommends Vote Election Proposal
Board Directors Recommends Vote Following Proposals Board Directors Time Turn Management Liquidation Torreypines Therapeutics
Board8221 Bonus Amounts
Borrowers Books Bridging Administration
Broad-based Benefit Plans Building
Business Business Combination Torreypines Therapeutics Inc
Business Entertainment Gifts Business Expenses Benefits
Business Harmed Fail Protect Intellectual Property Business Strategy
Bylaws Calculation Payment Royalties Percentage Sublicense Fees
Cannot Assure Exact Amount Timing Distribution Stockholders Plan Cannot Assure Fda Approval Potential Products Government Regulation
Cannot Assure Future Revenue Operating Profits Lose Entire Capital Stock Represented Within Certificate Hereby Irrevocably Constitute
Capitalization Adjustments Captions
Carrying Value Investment Oxis International Face Future Impairment Cash Bonus
Cash Equivalents Cause
Caution Against Forward-looking Statements Certain Related-person Transactions
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certain Warrant Purchase Stock Issued Torreypines Therapeutics Inc Certificate
Certificate Chief Executive Officer Certificate Chief Financial Officer
Certificate Incorporation Bylaws Charters Codes Conduct Certificate Incorporation Bylaws Directors Officers
Certificate Incorporation Torreypines Therapeutics Inc Certification
Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act Certifications
Certified Copy Certifies
Cessation Trading Common Stock Closing Transfer Books Chairman Board
Chairman Board Neurogenetics Inc Change Control
Change Control Registrant Change Control Severance Benefits
Change Control Severance Payments Change Independent Registered Public Accounting Firm
Change Vote After Submitting Proxy Changes Business Ownership Management Locations Collateral
Changes Compensation Changes Control Registrant
Changes Disagreements Accountants Accounting Financial Disclosure Changes Internal Control Over Financial Reporting
Changes Internal Controls Changes Interpretations Accounting Rules Regulations Result Unfavorable Charges
Changes Registrants Certifying Accountant Check Appropriate Box Below Form 8-k Filing Intended
Chi-square Test Contrast Placebo Sang Cephalalgia Chief Executive Officer
Chief Financial Officer Secretary Choice Law
Clarifying Questions Concerns Reporting Possible Violations Classic Design Award Winning Research
Clinical Development Opportunities Clinical Development Overview-ngx426
Clinical Development Overview-tezampanel Clinical Development Status
Clinical Trial Design Clinical Trials Product Candidates Not Produce Successful Results
Closing Closing Date
Closing Effective Time Closing Torreypines Transfer Books
Cobra Code
Code Business Conduct Ethics Cognitive Impairment Associated Schizophrenia Alzheimers Disease
Cognitive Impairment Associated Schizophrenia Cias Collaboration Agreement
Collateral Combinations
Combined Board Directors Consist Current Torreypines Axonyx Combined Executive Team
Combined Investment Highlights Commercial Recording Division
Commercial Sale Commitments
Commitments Contingencies Commitments Other Matters
Committee Common Area
Common Stock Common Stock Delisted Nasdaq Market Transfer Books Close
Common Stock Warrant Liability Communications Board Directors
Companies Anticipate Several Key Milestones Related Product Candidates Companies Universities Licensed Product Candidates Clinical Development Marketing
Companies Universities Licensed Product Candidates Research Clinical Development Compared 2003
Compared 2004 Comparison 2006 2005
Comparison 2007 2006 Comparison 2008 2007
Comparison 2009 2008 Comparison Cumulative Total Return
Compensation Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Committee Report Executive Compensation Directors
Compensation Discussion Analysis Competition
Competition Fair Dealing Competitors Products Approved Faster Marketed Effectively Demonstrated Effective
Complete Disability Complete Outgoing Wire Request Below Portion Funds Loan
Completion Acquisition Disposition Assets Compliance
Compliance 409a Code Compliance 409a Internal Revenue Code
Compliance Certificate Compliance Laws Rules Regulations
Compliance Procedures Compliance Resources
Comprehensive Income Loss Comprehensive Loss
Conclusion Conclusion Regarding Effectiveness Disclosure Controls Procedures
Condensed Consolidated Balance Sheets Condensed Consolidated Statements Operations
Condition Leased Premises Quiet Enjoyment Conditions Precedent Credit Extensions
Conditions Precedent Initial Credit Extension Conditions Precedent Obligations Tpt
Conduct Supervision Conference Call Operator
Conference Call Webcast Information Confidential
Confidential Information Confidentiality
Confidentiality Agreement Confirmed Agreed
Conflicts Interest Consent
Consent Independent Registered Public Accounting Firm Consents
Consequences Person Group Becoming Acquiring Consideration
Consolidated Statements Operations Constituent Corporation
Consultancy Contact
Contemplated Transactions Contingencies
Contingent Liabilities Contingency Reserve Contingent Obligation
Continuation Indemnity Continue Incur Claims Liabilities Expenses Reduce Amount Available
Continue Incur Losses Foreseeable Future Might Never Achieve Contract
Contracts Contributions
Control Controls Procedures
Cooperation Cooperation Agreement
Cooperation Parties Copy
Copy Annual Report Securities Exchange Form 10-k 2007 Copy Resolutions
Copyrights Corporate Action Constituting Grant Stock Awards
Corporate Governance Nominating Committee Corporate Governance Principles
Corporate Opportunities Corporate Transaction
Corporation Costs
Costs Sales Counterparts
Covenant Default Covenants
Covenants Exercise Shares Coverage
Craig Johnson Craig Johnson Chief Financial Officer
Craig Johnson Employee Offer Letter Credit Extension
Credit Facility Comerica Bank Includes Restrictive Financial Covenant Critical Accounting Policies
Critical Accounting Policies Estimates Critical Accounting Policies Significant Judgments Estimates
Cure Llc Public Health Service National Institutes Current Collaborations Remain Intact
Current Report Current Report Pursuant Securities Exchange Act 1934
Current Treatments Alzheimers Disease Current Treatments Cognitive Impairment Associated Schizophrenia
Current Treatments Migraine Currently Not Compliance Nasdaq Rules Regarding Minimum Bid
Customer Identification Daewoong Pharmaceutical Ltd
Damage Destruction Eminent Domain Data Exclusivity Period
Data Meet Pre-defined Criteria Continuing Trial Enrollment Top Dated
Decide Liquidating Trust Interests Stockholders Such Not Transferable Defendant Class Action Lawsuit Determined Adversely Material Adverse
Defendant Class Action Lawsuit Shareholder Derivative Determined Adversely Defendant Class Action Lawsuit Stockholder Derivative Determined Adversely
Deferrals Definition Change Control
Definitions Delays Commencement Completion Clinical Testing Product Candidates Result
Delegation Committee Department Microbiology Molecular Genetics University California Irvine Co-authored
Departure Directors Certain Officers Election Appointment Compensation Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Certain Officers Election Appointment Compensatory Arrangements Departure Directors Principal Officers Election Appointment
Depend Contract Research Organizations Much Pre-clinical Clinical Testing Depend Eisai Ltd Funding Alzheimers Disease Genetics Discovery
Dependent Executive Officers Non-employee Scientific Personnel Description Business
Description Property Descriptive Headings
Designated Outside Counsel Designation Beneficiary
Despite Confidentiality Agreements Proprietary Rights Themselves Limited Effectiveness Details Proposed Raptor Torreypines Merger
Determination Date Development License Agreement
Development Licensing Agreements Development Plan
Developments Serono International Difficulty Unable Restart Clinical Development Programs Merger Raptor
Director Attendance Annual Meeting Director Compensation
Director Independence Director Nomination Process
Directors Executive Officers Corporate Governance Directors Officers
Directors Registrant Directors Retiring 2007
Disclaimer Disclosure
Disclosure Licensed Know-how Discrepancy
Discretionary Annual Cash Bonus Discrimination Harassment
Dispositions Dispute Notice
Dispute Resolution Dissenting Shares
Dissolution Liquidation Distinctly Different First-in-class
Distribution Assets Distribution Shares Common Stock
Distributions Investments Dividends
Dividends Subdivisions Combinations Reclassifications Documents Incorporated Reference
Drug Candidates Not Achieve Market Acceptance Business Never Drug Discovery Programs
Drug Regulatory Agency Dtc
Due Diligence Due Eli Lilly Ngx426 Tezampanel
Due Organization Authorization Duration Amendment Termination
Duties Early Termination
Ecitals Effect
Effect Certain Corporate Transactions Effect Other Employee Benefit Plans
Effect Termination Effect Termination Surviving Obligations
Effective Date Effective Date Plan
Effective Time Effectiveness Registration Statement
Effects Merger Efforts Discover New Product Candidates Not Succeed Recommend
Eisai Eisai Ltd
Eisai Ltd Agreement Election Directors
Electronic Delivery Electronic Delivery Future Stockholder Communications
Electronic Delivery Proxy Materials Elements Executive Compensation
Eli Lilly Eligibility
Eligible Employee Emea
Employee Employee Benefit Plan
Employee Benefit Plans Employee Benefits
Employee Stock Purchase Plan Employees
Employment Agreement Employment Agreement Graham
Employment Agreement Johnson Employment Agreement Kurtz
Employment Agreement Schneider Employment Agreements
Employment Agreements Including Change Control Severance Provisions Certain Employment Contracts Executive Officers Termination Change-in-control Arrangements
Employment Other Service Rights Employment Taxes
Encumbrance Endpoints Reducing Capsaicin-induced Pain Healthy Subjects
Entire Agreement Entire Agreement Amendments
Entire Agreement Counterparts Exchanges Facsimile Entire Agreement Modification
Entity Entry Material Definitive Agreement
Environmental Compliance Environmental Law
Environmental Laws Environmental Matters
Equity Awards Equity Compensation
Equity Compensation Plan Information Equity Incentive Plan
Equity Method Accounting Investments Common Stock Erisa
Erisa Plan Establish Strategic Alliances Maximize Commercial Potential Product Candidates
Estimated Net Cash Schedule Estimates
Evaluation Disclosure Controls Procedures Evaluation Executive Compensation Package
Evaluation Executive Compensation Package Following Merger Evelyn Graham
Evelyn Graham Chief Operating Officer Even Product Candidates Receive Regulatory Approval They Still
Exact Name Registrant Specified Charter Except Specifically Noted Following Information Other Contained Herein
Exceptions Exchange
Exchange Act Exchange Agent
Exchange Fund Exchange Rate Manner Place Payment
Exchange Ratio Exclusive Remedy
Executed Holder Desires Exercise Rights Certificate Other Pursuant Executed Holder Desires Exercise Rights Certificate Purchase Shares
Execution Documents Executive Agreements
Executive Compensation Executive Compensation Prior Merger
Executive Director Compensation Process Executive Officers
Executive Officers Registrant Exercisability
Exercise Exercise Holder
Exercise Period Exercise Price
Exercise Prior Vesting Early Exercise Purchase Rights
Exercise Shares Exhibits
Existing Axonyx Policies Existing Torreypines Policies
Expand Business Development Initiatives Across Pipeline Expansion Business Development Activities
Expect Complete Phase Iib Clinical Trial Tezampanel 2007 Expect Continue Incur Net Operating Losses Next Several
Expect Dissolution Process Completed Expect Terminate Registration Common Stock Exchange Act Substantially
Expected Distributions Stockholders Timing Expenses
Expenses8221 Expiration
Explanatory Fail Attract Keep Key Management Scientific Personnel Unable
Fail Attract Keep Key Management Unable Develop Commercialize Fail Comply Terms Licensing Agreements Licensors Terminate Certain
Fail Enter Maintain Collaborations Product Candidates Reduce Delay Fail Establish Maintain Collaborations Partners Not Perform Unable
Fail Keep Pace Rapid Technological Change Biotechnology Pharmaceutical Fair Dealing
Fair Value Financial Instruments Fda
Federal Income Tax Information Fees
Fees Billed Eisner Llp 2004 2003 Fiduciary Duties
Final Final Net Cash Schedule
Final Record Date Final Study Reports
Financial Advisor Financial Overview
Financial Results Financial Statement Presentation
Financial Statements Financial Statements Exhibits
Financial Statements Reports Certificates Financial Statements Supplementary Data
Find Additional Information Merger Find Information
Find Out Results Voting Annual Meeting Finra
Firpta Certificate Fluctuations Currency Exchange Rates Negatively Impact Business
Fluctuations Operating Results Fluctuations Quoted Price Oxis Commons Stock Adversely Affect
Force Majeure Foreign Currency Translation Transactions
Foreign Regulation New Drug Compounds Form 10-k
Form 10-q Form Assignment Executed Registered Holder Such Desires Transfer
Form Irrevocable Proxy Form Payoff Letter
Form S-4 Registration Statement Form S-8
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statements Forwarding Address Copies Process Sent Secretary State Nevada
Fractional Shares Full Disclosure
Further Action Further Assurances
Further Stockholder Approval Required Gaap
Gamma-secretase Modulator Drug Discovery Program Gamma-secretase Modulator Program
Gender General
General Administrative General Administrative Expense
General Authorization General Disclosure Package
General Information Generic Competition
Generic Competition Alzheimers Drugs Currently Market Materially Impact Genetics Research Program Cooperation Agreement
Gifts Entertainment Going Concern Considerations
Going Concern Managements Plan Good Reason
Gosse Bruinsma Gosse Bruinsma Colin Neillseptember 2005 Paul Feuerman
Gosse Bruinsmas Colin Neillpaul Feuerman Governance
Governing Law Governing Plan Document
Government Compliance Government Regulation
Governmental Authorization Governmental Body
Governmental Proceedings Relating Contemplated Transactions Right Operate Business Graham
Graham Development Experience Proven Track Record Establishing Running Grant Purchase Rights Offering
Grant Security Interest Grants Plan-based Awards
Grants Plan-based Awards 2008 Greement
Growth Capital Advance Growth Capital Commitment Termination Date
Growth Capital Funding Date Growth Capital Loan Commitment
Guaranty Had Clinical Trial Failures Lead Compound
Hazardous Chemicals Biological Materials Business Claims Relating Improper Hazardous Chemicals Radioactive Biological Materials Business Claims Relating
Hazardous Materials Headings
Health Care Reform Measures Party Reimbursement Practices Uncertain Health Safety
Held 2007 Held 2008
Held 2009 Help Answer Questions
Highlights Holders
Holders Record Quorum Honest Ethical Conduct
Householding Proxy Materials However
Hsr Act Identical Counterparts Facsimile
Identification Audit Committee Financial Expert Immediate Release
Impairment Impairment Long-lived Assets Held Sale
Impairment Rights Imputation
In-process Research Development Inapplicability Anti-takeover Statutes
Incentive Stock Option 100000 Limitation Income Taxes
Incorporated Laws State Delaware Ind
Indebtedness Indebtedness Payments
Indemnification Indemnification Waiver Limitation Landlords Liability
Indemnified Parties Indemnity Agent
Indemnity Agreement Independence Board
Independence Board Directors Index
Index Consolidated Financial Statements Index Exhibits
Information Concerning Board Directors Committees Thereof Information Regarding Committees Board
Information Regarding Committees Board Directors Insider Trading
Insolvency Insolvency Proceeding
Insurance Intellectual Property
Intended Address Unmet Needs Migraine Sufferers Interest Expense
Interest Income Interest Rate
Interests Directors Officers Plan Dissolution Internal Control Integrated Framework
International Business Laws Interpretation Certain Agreements
Introduction Inventory
Inventory Returns Investment
Investment Assurances Investment Oxis
Investment Oxis International Inc Investments
Issuer Free Writing Prospectus Issuer General Free Writing Prospectus
Jason Fisherman Jean Deleage Phd
John Quirk Johnson Development Corporation
Joint Proxy Statement Prospectus Jolla 2006
Jolla 2007 Jolla 2008
Judgments Key Employee
Key Terms Transaction Know-how
Knowledge Kurtzs Career Includes Senior Positions Boots Pharmaceuticals Bayer
Language Largest Stockholders Take Actions Contrary Interests Including Selling
Lead Agonist Cognitive Disorders Lease Agreement
Leased Premises Legal Compliance
Legal Fees Legal Proceeding
Legal Proceedings Legal Requirement
Legends Lenders Expenses
Lenders Liability Collateral Liabilities
Liability License Agreement
License Grant Licensed Compound
Licensed Know-how Licensed Patents
Licensed Product Licensed Rights Product Candidates Ngx267 Ngx292 Life Science
Licensed Rights Product Candidates Ngx267 Ngx292 Lsri Termination Licensed Rights Product Candidates Ngx426 Tezampanel Eli Lilly
Licensed Rights Product Candidates Tezampanel Ngx426 Eli Lilly Lien
Lien Priority Life Science Research Israel
Life Science Research Israel Lsri Life Science Research Israel Ltd
Limitation Liability Limitations Additional Indemnity
Limited Operating History Large Accumulated Deficit Never Become Liquidating Distributions Nature Amount Timing
Liquidating Trust Liquidity Capital Resources
List Subsidiaries Listing
Listing Trading Common Stock Interests Liquidating Trust Trusts Litigation
Loan Advance Paydown Request Form Loan Agreement Oxford Finance Corporation Silicon Valley Bank
Loan Documents Loan Payment
Loan Payment Advance Request Form Loan Security Agreement
Location Lock-up Agreement
Long Term Compensation Awards Securities Underlying Options Long-lived Assets
Long-term Debt Long-term Equity Incentive Awards
Lose Key Personnel Unable Attract Retain Additional Pursue Lost Stolen Mutilated Destroyed Warrant
Louis Cornacchia Loyalty
Ly293558 Dose Maintain Balanced Diversified Cns Portfolio Respect Development Time
Maintenance Corporate Books Records Documents Accounts Financial Integrity Management Broad Discretion Over Cash Not Effectively Adversely
Management Broad Discretion Over Cash While Expended Significant Management Organization
Management Required Devote Substantial Time Comply Public Regulations Managements Annual Report Internal Control Over Financial Reporting
Managements Discussion Analysis Financial Condition Results Operations Managements Report Internal Control Over Financial Reporting
Manufacturing Supply March-april 2006 Edition133
Market Common Equity Related Stockholder Matters Issuer Purchases Market Information
Market Price Common Stock Market Price Stock Adversely Affected Volatility
Market Segments Marketing Sales
Markets Seek Participate Intensely Competitive Competitors Larger Experience Marvin Hausman
Marvin Hausman Remains Chairman Board Mask Works
Material Adverse Change Material Adverse Effect
Material Deterioration Financial Statements Material Modification Rights Security Holders
Material Report Not Soliciting Deemed Filed Sec Incorporated Material Tax Accounting Implications Executive Compensation Policies
Material United States Federal Income Tax Consequences Dissolution Maximize Value Versatile Lead Compounds
Mechanism Action Media Public Discussions
Medical Meetings Board
Meetings Board Directors Member Board Directors
Mendment Merger
Merger Agreement Merger Costs
Merger Sub Torreypines Mergers Acquisitions
Method Payment Methods Used Board Directors Management Estimating Values Assets
Michael Murphy Chief Medical Officer Michael Murphy Phd
Might Face Intellectual Property Claims Costly Resolve Divert Migraine
Migraine Chronic Pain Milestone Payments
Minimum Payment Sublicense Fee Miscellaneous Provisions
Misrepresentations Mitigation
Model Modification Voting Covenant
Modifications Waiver Multiemployer Plan
Multiple Employer Plan Multiple Opportunities Commercial Success
Multiple Roas Muscle Spasticity Rigidity
Mutual Representations Warranties Name Jurisdiction Organization Constituent Entity Resulting
Name Person Filing Proxy Statement Other Registrant Nasdaq
Nasdaq Stock Market Llc Name Each Exchange Registered Nda
Need Additional Funds Unable Raise Them Curtail Cease Need Liquidate Voluntary Dissolution Delaware Law Seek Protection
Need Substantial Additional Funding Unable Raise Capital Needed Neil Kurtz
Neil Kurtz Currently President Chief Executive Officer Neil Kurtz Employee Offer Letter
Neil Kurtz President Chief Executive Officer Net Cash
Net Cash Calculation Net Loss
Net Loss Per Share Net Sales
Neurogenetics Commercialization Obligation Neurogenetics Inc
Neuron Neuropathic Pain
Neurotoxicity Studies New Accounting Pronouncement
New Accounting Pronouncements New York 10018
New York 2005 New York 2005 Axonyx Inc Nasdaq Axyx
New York 2006 New York University License
Ngx267 Ngx267 Being Developed Treat Xerostomia Dry Mouth Currently
Ngx267 Ngx292 Ngx267 Ngx292 Being Developed Cias Indication Products Approved
Ngx267 Ngx292 Being Developed Treat Xerostomia Dry Mouth Ngx267 Ngx292 Treatment Cias Alzheimers Disease
Ngx267 Ngx292-muscarinic Receptor Agonists Ngx426
Ngx426 Oral Prodrug Tezampanel Ngx426 Tezampanel Belong New Class Compounds Received Regulatory
Ngx426 Treatment Migraine Ngx555 Alzheimers Disease
Nominees Director Non-contravention Consents
Non-exclusivity Non-exclusivity Rights
Non-solicitation Non-survival Representations Warranties
Non-transferability Non-waiver
Nonqualified Deferred Compensation Not Able Complete Merger Raptor Failure Adversely Affect
Not Able Continue Going Concern Need Substantial Additional Not Complete Clinical Trials Time Expected Delay Prevent
Not Currently Capability Undertake Manufacturing Marketing Sales Potential Not Internal Manufacturing Capabilities Fail Develop Maintain Supply
Not Pay Cash Dividends Not Result Stronger Technologies Clinical Programs Companies Compatible
Not Undertake Discuss Matters Relating Ongoing Clinical Trials Notes Payable
Notice Notice Annual Meeting Stockholders
Notice Exercise Notice Opportunity Defend
Notices Notices Etc
Notices Record Date Notification Defense Claim
Novato California 2009 Now Therefore
Number 000-25571 Number Securities Remaining Available Future Issuance Equity Compensation
Number Shares Number Shares Exercise Price
Nx426 Objectives Philosophy Executive Compensation
Obligation Notify Obligations
Obligations Raptor Off-balance Sheet Arrangements
Offering Offerings
Officer Officers
Only Limited Trading Market Common Stock Possible Investors Only Limited Trading Market Common Stock Possible Not
Operating Segments Option Exercises Stock Vested 2006
Option Exercises Stock Vested 2007 Option Exercises Stock Vested End
Option Grants 2004 Option Not Service Contract
Option Provisions Ordinary Course Business
Organization Business Other Acetylcholinesterase Inhibitors
Other Agreements Other Compounds Axonyx Drug Portfolio
Other Events Other Fees
Other Income Expense Other Indications
Other Information Other Matters
Other Pertinent Information Other Proceedings
Other Remedies Specific Performance Other Toxicology Studies Reports
Other Words133 Out-licensed Technology
Outstanding Equity Awards Year-end Overview
Ownership Ownership Inventions
Page Page Number
Pain Franchise Tezampanel Ngx426 Parachute Payments
Part Part Other Information
Part Restructuring Reduction Workforce Described 205 Above Employment Partial Exercise Holder
Partial Indemnification Participant
Participants Solicitation Participation Plan
Participation Withdrawal Termination Parties Contemplate Executive Employee Parent Tptx Amounts Required
Party Party Beneficiaries
Party Co-ownership Concerning Certain In-licensed Patent Rights Affect Patent Applications
Patents Patents Trademarks Copyrights
Patrick Van Beneden Paul Schneider
Payable Paying Proxy Solicitation
Payment Default Payment Liquidating Distributions Stockholders Delayed
Payment Purchase Price Payroll Deductions Payment Stock Awards Lieu Exercise
Payments Government Personnel Pending Foreign Applications
Pension Benefits Performance Affiliates
Performance Awards Performance Covenants
Performance Graph Permitted
Permitted Free Writing Prospectus Permitted Indebtedness
Permitted Investments Permitted Liens
Permitted Transfers Person
Peter Davis Phd Phase Clinical Trial Patients Xerostomia
Phase Iia Phenserine
Phenserine Alzheimers Disease Phenserine Development Program
Pinprick Hyperalgesia N15 Placement
Placement Agent Plan Liquidation Dissolution
Plan Location Leased Premises Designated Plan Term
Please Indicate Compliance Status Circling Yes Complies Column Please Supply Genuine Signatures Authorized Signers Below
Policy Audit Committee Pre-approval Non-audit Services Independent Auditor Political Contributions
Posiphen Posiphen Alzheimers Disease
Posiphen Development Program Positive Proof Concept Studies
Possession Post-merger Profile Torreypines
Post-merger Torreypines Executive Team Potential Litigation Concerning Patent Rights Involve Significant Expenses
Potential Technological Changes Field Business Create Considerable Uncertainty Potential Treatments Alzheimers Disease
Potential Treatments Cognitive Impairment Associated Schizophrenia Potential Treatments Migraine Chronic Pain
Power Attorney Pre-approval Policies Procedures
Pre-approval Policy Pre-closing Period
Preclinical Documents Preferred Stock
Preferred Stock Provisions Premises
Prepared 2006 Prepayment Fee
Press Release Contains Conference Call Audio Webcast Contain Press Release Contains Forward-looking Statements Predictions Including Regarding
Press Release Contains Forward-looking Statements Predictions Such Include Principal Accountant Fees Services
Principles Consolidation Private Placement
Private Placement Agreement Private Securities Litigation Reform Act
Pro Forma Pro Forma Condensed Combined Financial Statements
Pro Forma Financial Information Pro Forma Information Sfas 123 Periods Prior 2006
Pro Forma Purchase Accounting Adjustments Proceeding8221
Proceeds Process Identifying Evaluating Candidates
Product Candidates Clinical Development Cannot Certain Successfully Developed Product Candidates Early Stage Development Cannot Certain Successfully
Product Candidates Early Stage Development Only Portion Clinical Product Candidates New Therapies Chronic Pain Cias Alzheimers
Product Candidates Not Achieve Market Acceptance Among Physicians Product Candidates Not Successfully Complete Clinical Trials Required
Product Candidates Subject Extensive Regulation Costly Time Consuming Product Development Programs
Product Liability Claims Harm Business Insurance Coverage Those Product Liability Lawsuits Successfully Brought Against Incur Substantial
Products Available Sale Never Successful Developing Suitable Commercialization Profile Combined
Proforma Information Sfas 123 Periods Prior 2006 Program
Prohibited Payments Project Property
Promise Pay Properties
Property Equipment Proposal Ratification Appointment Eisner Llp Independent Auditors
Proposed Merger Raptor Pharmaceuticals Corp Proprietary Information Inventions Agreement
Proprietary Rights Prospectus
Prospectus Delivery Period Protection Proper Assets
Provided Provided Further
Provided However Proxy
Proxy Card Valid Only Signed Dated Proxy Revocation Procedure
Proxy Solicitation Proxy Solicited Behalf Board Directors
Proxy Statement Accompanying Card Being Mailed 2009 Proxy Statement Pursuant Securities Exchange Act 1934 Amendment
Public Reporting Publication Code Business Conduct Ethics Amendments Waivers
Publications Purchase Agreement
Purchase Date Purchase Period
Purchase Price Purchase Right
Purchase Rights Price Purchase Stock
Purchased In-process Research Development Purchased In-process Research Development Expense
Purchased Patents Purpose
Pursuant 265 Delaware General Corporation Law Quantitative Qualitative Disclosures Market Risk
Quarterly Results Raising Additional Funds Issuing Securities Through Collaboration Licensing
Rapid Conversion Tezampanel After Oral Ngx426 Raptor Pharmaceutical Corp
Raptor Pharmaceuticals Corp Raptor Pharmaceuticals Corp Torreypines Complete Merger
Ratification Selection Independent Registered Public Accounting Firm Real Property Leasehold
Reasons Dissolution Reasons Plan Dissolution
Receiving Materials Recent Accomplishments
Recent Accounting Pronouncements Recent Board Management Changes
Recent Developments Recent Events
Recently Issued Accounting Pronouncements Recently Issued Accounting Standards
Recitals Reclassification
Reclassifications Recommendation Board Directors
Record-keeping Records Audits
Redeemable Convertible Preferred Stock Redemption
Reduction-in-force Refer Axonyx Inc Annual Report Form 10-k 2005
Registered Organization Registrable Merger Shares
Registrants Telephone Number Including Area Code 212 645-7704 Registrants Telephone Number Including Area Code 858 623-5665
Registrants Telephone Number Including Area Code 858-623-5665 Registration Statement
Regulation Disclosure Regulation Disclosure 801 Other Events
Regulatory Regulatory Approval
Regulatory Approvals Regulatory Compliance
Regulatory Matters Reimbursement Pricing
Reincorporation Reincorporation Axonyx Reverse Split Common Stock
Related Corporation Related Party Transaction
Related-party Transactions Related-person Transactions Policy Procedures
Relationship Between Parties Release
Release Waiver Claims Rely Parties Assist Conducting Clinical Trials Not Successfully
Remainder Page Intentionally Left Blank Remedies
Remedies Cumulative Rent Tenants Charges
Rentable Area Reorganization Reclassification Merger Consolidation Disposition Assets
Repayment Credit Extensions Growth Capital Advances Report Audit Committee Board
Report Audit Committee Board Directors Report Ernst Young Llp Independent Registered Public Accounting
Report Independent Registered Public Accounting Firm Reporting Requirements
Reporting Violations Policies Receipt Complaints Regarding Financial Accounting Representations Warranties Lsri
Representatives Required Stockholder Vote
Required Suspend Repeat Terminate Clinical Trials Not Meet Required Torreypines Stockholder Vote
Required Vote Resale Registration Statement
Research Development Research Development Expense
Research Field Research Funding
Research License Agreement Research Plan
Research Program Research Technology
Research Term Response
Response Date Responsible Officer
Restraints Restricted Stock Unit Agreements
Restricted Stock Unit Award Agreement Restricted Stock Units
Restriction Transfer Subject Securities Restriction Transfer Voting Rights
Restrictions Transfer Results Operations Financial Condition
Return Assets Revenue
Revenue Recognition Revenues
Reverse Stock Split Reincorporation Review Discussions Independent Accountants
Review Management Right Repurchase
Right Set-off Rights
Rights Agent Rights Agreement
Rights Agreement Amendment Rights Bankruptcy
Rights Remedies Rincipal Tockholder
Risk Factors Considered Stockholders Deciding Whether Approve Plan Risks Related Business
Risks Related Common Stock Risks Related Industry
Roas Royalties
Royalty Term Rules Regulations
Ruth Group Safe Harbor
Sale Assets Sales Assets
Sales General Administrative Sales Marketing
Sarbanes-oxley Act Sarbanes-oxley Act 2002
Sarbanes-oxley Certifications Schedule Exceptions
Schedule Lease Terms Scn Pf40
Secretase Modulator Tptx Discovery Program Securities
Securities Exchange Act 1934 Amendment Securities Law Compliance
Securities Registered Pursuant Act Security Agreement
Security Ownership Certain Beneficial Owners Management Security Ownership Certain Beneficial Owners Management Related Stockholder
See Accompanying Notes See Notes Consolidated Financial Statements
Selected Quarterly Data Send Stock Certificates Now
Separability Series Warrants
Services Seventh Avenue 10th Floor New York 10018 Address
Severability Severability Provision
Severance Payments Shareholder Rights Plan
Shareholders Shares
Shares Common Stock Subject Plan Shares Subject Plan
Shares Used Calculating Basic Diluted Net Loss Per Shelf Registration Statement
Signature Signature Page Follow
Signature Page Loan Security Agreement Signature Page Party Security Agreement
Signature Page Warrant Purchase Stock Signature Signed
Signatures Solvency
Sound Science Skilled Team Smart Business Model Special Ethics Obligations Employees Financial Reporting Responsibilities
Specific Performance Statistically Significant
Steven Ferris Phd Steven Ratoff
Steven Wagner Chief Scientific Officer Steven Wagner Phd
Still Sell Shares Torreypines Therapeutics Inc Common Stock Stock Awards Assumed
Stock Awards Held Current Participants Stock Awards Held Persons Other Current Participants
Stock Matters Redemption Cancellations Stock Option Agreement Incentive Nonstatutory
Stock Option Grants Stock Options
Stock Price Been Expected Continue Volatile Stock Price Been Expected Volatile Market Common Drop
Stock Price Performance Graph Stock Subject Purchase Plan
Stock-based Compensation Stockholder
Stockholder Approval Stockholder Approvals Merge
Stockholder Communications Board Stockholder Communications Board Directors
Stockholder Proposals Stockholder Proposals 2006 Annual Meeting
Stockholder Proposals Due Next Annual Meeting Stockholder Record Shares Registered Name
Stockholder Rights Stockholder Rights Plan
Stockholders Vote Against Plan Dissolution Very Difficult Continue Strategic Alliance License Other Commercial Agreements
Strategic Partners Not Devote Adequate Resources Development Commercialization Streamline Operations
Strike Paragraph Not Apply Study Results
Subject Extensive Government Regulation Fail Receive Regulatory Approval Subject Securities
Subject Uncertainty Relating Health Care Reform Measures Reimbursement Sublicense Fee
Sublicensee Sublicenses
Submission Matters Vote Security Holders Subordinated Debt
Subrogation Subsequent Event
Subsequent Events Subsidiaries
Subsidiary Substantially Product Candidates Early Stage Development Only Portion
Success Business Depends Ability Successfully In-license Compounds Develop Success Depends Ability Protect Intellectual Property Proprietary Technologies
Successors Assigns Sued Infringing Intellectual Property Rights Parties Costly Time
Summary Benefits Executive Officers Summary Compensation
Summary Compensation Table Summary Plan Dissolution Process
Summary Term Sheet Superior Offer
Survival Survival Certain Sections
Surviving Corporation Susan Mellberg
Symptomatic Improvement Table Contents
Table Patent Status Tax
Tax Consequences Tax Fees
Tax Return Tax Treatment Liquidating Distributions Vary Stockholder Discussions Proxy
Tax Withholding Taxes
Tenants Proportionate Share Term
Term Loan Termination
Termination Cause Termination Commitment Lend
Termination Death Disability Termination Employment
Termination Executive Termination Lsri
Termination Material Definitive Agreement Termination Mutual Agreement Parties
Termination Neurogenetics Termination Payments
Termination Reason Other Cause Terms
Tezampanel Tezampanel Administration
Tezampanel Ngx424 Ngx426 Tezampanel Ngx426
Tezampanel Ngx426 Ampa Kainate Receptor Antagonists Tezampanel Ngx426 Belong New Class Compounds Received Regulatory
Tezampanel Ngx426 Ngx555 Belong New Classes Compounds Received Tezampanel Ngx426-ionotropic Glutamate Receptor Antagonists Ampa Kainate Subtype
Tezampanel Properties Tezampanel Treatment Migraine
Therefore Not Know Whether Product Candidates Yield Commercially Time Devoted Services
Time Essence Title
Title Assets Title Class
Title Securities Tockholder
Torreypines Torreypines Affiliate
Torreypines Announces Adjournment Special Meeting Stockholders Torreypines Associate
Torreypines Board Recommendation Torreypines Cancels Special Meeting Stockholders Order Pursue Merger
Torreypines Contact Torreypines Contract
Torreypines Designated Directors Torreypines Disclosure Schedule
Torreypines Employee Plan Torreypines Financials
Torreypines Financing Torreypines Host Conference Call Webcast Edt Today Audio
Torreypines Interim Balance Sheet Torreypines Material Adverse Effect
Torreypines Material Contract Torreypines Near-term Deliverables
Torreypines Options Torreypines Permits
Torreypines Permitted Transaction Torreypines Preferred Stock
Torreypines Receives Notice Delisting Nasdaq Global Market Torreypines Registered
Torreypines Regulatory Permits Torreypines Rights
Torreypines Rights Agreement Torreypines Stock Certificate
Torreypines Stock Option Plan Torreypines Stockholder Approval
Torreypines Stockholders Meeting Torreypines Therapeutics
Torreypines Therapeutics Announces Board Directors Approval Plan Liquidation Torreypines Therapeutics Completes Merger Axonyx
Torreypines Therapeutics Host Conference Call Webcast Est Today Torreypines Therapeutics Inc
Torreypines Therapeutics Inc 2000 Equity Incentive Plan Stock Torreypines Therapeutics Inc Index Consolidated Financial Statements
Torreypines Therapeutics Present Thomas Weisel Partners 2006 Healthcare Torreypines Therapeutics Receives Nasdaq Deficiency Notice
Torreypines Therapeutics Receives Notice Non-compliance Nasdaq Torreypines Therapeutics Reduces Workforce Employees
Torreypines Therapeutics Reports 2008 Results Recent Accomplishments Torreypines Therapeutics Reports 2009 Financial Results
Torreypines Therapeutics Reports Full 2008 Results Torreypines Therapeutics Reports Successful End-of-phase Meeting Fda Tezampanel
Torreypines Therapeutics Sells Alzheimers Disease Genetics Program Eisai Torreypines Triggering Event
Torreypines Warrants Trademarks
Trademarks Trade Secrets Other Proprietary Information Tranche Closing Condition
Transaction Transactions Affiliates
Transfer Transfer Lilly Know-how Transition Support
Transfer Warrant Transferability
Treatment Outstanding Options Warrants Treatment Stock Options Warrants
Uncovered Litigation Damages Underlying Cause Not Just Symptoms
Unit United States
University Iowa Research Foundation Unregistered Sales Equity Securities
Unsecured Obligation Upcoming Milestones
Usc 1350 Utilities
Valid Claim Valid Issuance
Validation Criteria Value Received
Vesting Vitro
Vivo Vote
Vote Annual Meeting Vote Directors
Vote Internet Wwwproxyvotecom Vote Mail
Vote Phone 1-800-690-6903 Vote Special Meeting
Votes Votes Counted
Votes Needed Approve Each Proposal Votes Needed Approve Plan Dissolution
Voting Agreement Voting Covenant Expiration Date
Voting Covenant Prior Expiration Date Wagner Co-founded Torreypines Then Named Neurogenetics 2000 Chief
Waiver Waiver Breach
Waivers Warrant Shares
Warrants Website
What Broker Non-votes What Happen Assets Tezampanal Ngx426 Plan Dissolution Approved
What Happen Plan Dissolution Approved What Happen Plan Dissolution Not Approved
What Material United States Federal Income Tax Consequences What Mean Receive Proxy Card
What Quorum Requirement What Return Proxy Card Not Make Specific Choices
What Total Amount Payments Stockholders Receive What Voting
Whereas Whether Results Phase Iib Trial Predictive Subsequent Trials
William Comer Phd Withdrawal
Withholding Obligations Witness Whereof
Witness Whereof Caused Warrant Executed Duly Authorized Representative Witness Whereof Parties Caused Agreement Executed Date Above
Xerostomia Xhibit 1015
Xhibits Disclosure Schedules Xonyx
Xvi Rights Reserved Landlord Rules Regulations Xviii Parking
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki